Listing 1 - 10 of 60 | << page >> |
Sort by
|
Choose an application
Huntington's Disease (HD) is a progressive neurodegenerative disease leading to a variety of neurological and psychiatric symptoms such as chorea, parkinsonism, oculomotor symptoms, cognitive decline, depression, suicidal ideation, and psychosis. Currently, only symptomatic treatment is available. In recent years, there has been a growing number of publications regarding pathophysiology, disease biomarkers, and possible avenues for causal therapy of HD. This book presents an overview of the most important research updates in the pathophysiology and treatment of HD, with particular reference to advances in HD neuropathology, neuroimaging, and biomarkers of HD. We also summarize possible new therapeutic targets, including cannabis-based medicine, cellular, and cell-free therapeutics. Importantly, researchers from different regions of the world have contributed to this volume as we wanted to create a balanced, inclusive, and interdisciplinary review of the topics. We hope that with this book readers will be offered a compact summary of up-to-date trends in HD research which, ultimately, will enable better diagnosis and treatment for HD patients.
Choose an application
"Living with Huntington's Disease: Challenges, Perspectives and Quality of Life first discusses the variety of sleep disorders in Huntington's Disease, as well as how sleep quality can be associated with other important clinical symptoms. Although Huntington's disease is categorized as a movement disorder, the wide range of non-motor symptoms including cognitive impairment and behavioral abnormalities are considered by patients and their caregivers to be just as disabling as the motor symptoms. As such, the authors explore the importance of symptomatic treatment of Huntington's disease-related symptoms. Following this, the emotional and communicational issues in Huntington's disease and their interrelations are examined, including depressive symptomatology, anxiety, helplessness or anger, as well as verbal and non-verbal communication and assistive technology. Lastly, the authors describe current trends and efforts in gene therapy techniques and the improvements in health conditions of Huntington's disease patients and their families"--
Choose an application
Huntington's Disease (HD) is a progressive neurodegenerative disease leading to a variety of neurological and psychiatric symptoms such as chorea, parkinsonism, oculomotor symptoms, cognitive decline, depression, suicidal ideation, and psychosis. Currently, only symptomatic treatment is available. In recent years, there has been a growing number of publications regarding pathophysiology, disease biomarkers, and possible avenues for causal therapy of HD. This book presents an overview of the most important research updates in the pathophysiology and treatment of HD, with particular reference to advances in HD neuropathology, neuroimaging, and biomarkers of HD. We also summarize possible new therapeutic targets, including cannabis-based medicine, cellular, and cell-free therapeutics. Importantly, researchers from different regions of the world have contributed to this volume as we wanted to create a balanced, inclusive, and interdisciplinary review of the topics. We hope that with this book readers will be offered a compact summary of up-to-date trends in HD research which, ultimately, will enable better diagnosis and treatment for HD patients.
Choose an application
Choose an application
Huntington's Disease (HD) is a progressive neurodegenerative disease leading to a variety of neurological and psychiatric symptoms such as chorea, parkinsonism, oculomotor symptoms, cognitive decline, depression, suicidal ideation, and psychosis. Currently, only symptomatic treatment is available. In recent years, there has been a growing number of publications regarding pathophysiology, disease biomarkers, and possible avenues for causal therapy of HD. This book presents an overview of the most important research updates in the pathophysiology and treatment of HD, with particular reference to advances in HD neuropathology, neuroimaging, and biomarkers of HD. We also summarize possible new therapeutic targets, including cannabis-based medicine, cellular, and cell-free therapeutics. Importantly, researchers from different regions of the world have contributed to this volume as we wanted to create a balanced, inclusive, and interdisciplinary review of the topics. We hope that with this book readers will be offered a compact summary of up-to-date trends in HD research which, ultimately, will enable better diagnosis and treatment for HD patients.
Choose an application
Shattered Dreams--But Hope distills the experiences of Laquita and Elton Higgs in caring for two Huntington's Disease-affected daughters. They portray what two people of faith have learned about suffering, endurance, and love through the challenge of caring for a disabled loved one day after day.
Choose an application
Choose an application
The Special Issue “Juvenile Onset Huntington’s Disease” highlights the growing interest in understanding the unique aspects of this ultra-rare disorder. After decades of research, gene therapy trials are underway for Adult Onset Huntington’s Disease (AOHD). However, patients with Juvenile Onset Huntington’s Disease (JOHD) are often excluded from these efforts, leaving many questions regarding its phenomenology. The current issue includes seven articles spanning work on the difficult emotional experiences of parents of children with JOHD; a review of the clinical manifestations of JOHD; behavioral issues in JOHD; CAG repeat and age of motor onset; autonomic nervous system dysfunction; and abnormality in MRI metabolic markers. Finally, a review of the therapeutic advances is included, highlighting future possibilities of clinical trials in JOHD subjects. The HD community—patients, family members at-risk for HD, caregivers, health-care professionals and scientists—is keen on expanding our understanding of JOHD. In the flurry of research on AOHD, those with JOHD were seemingly ‘left behind.’ The study of patients who are afflicted early in life with HD has become imperative, with this Special Issue representing just the beginning of the required effort to address this urgent need.
Medicine --- Huntington’s disease --- CAG repeat --- mutant huntingtin (mHTT) --- therapeutics --- neurodegeneration --- juvenile Huntington’s disease --- pediatric Huntington’s disease --- early-onset Huntington’s disease --- personal experiences --- caregivers --- case series --- juvenile-onset Huntington’s disease --- T1-Rho --- neuroimaging --- behavioral regulation --- executive function --- trinucleotide repeat disorder --- CAG --- motor onset --- juvenile-onset Huntington’s Disease --- autonomic --- n/a --- Huntington's disease --- juvenile Huntington's disease --- pediatric Huntington's disease --- early-onset Huntington's disease --- juvenile-onset Huntington's disease --- juvenile-onset Huntington's Disease
Choose an application
The Special Issue “Juvenile Onset Huntington’s Disease” highlights the growing interest in understanding the unique aspects of this ultra-rare disorder. After decades of research, gene therapy trials are underway for Adult Onset Huntington’s Disease (AOHD). However, patients with Juvenile Onset Huntington’s Disease (JOHD) are often excluded from these efforts, leaving many questions regarding its phenomenology. The current issue includes seven articles spanning work on the difficult emotional experiences of parents of children with JOHD; a review of the clinical manifestations of JOHD; behavioral issues in JOHD; CAG repeat and age of motor onset; autonomic nervous system dysfunction; and abnormality in MRI metabolic markers. Finally, a review of the therapeutic advances is included, highlighting future possibilities of clinical trials in JOHD subjects. The HD community—patients, family members at-risk for HD, caregivers, health-care professionals and scientists—is keen on expanding our understanding of JOHD. In the flurry of research on AOHD, those with JOHD were seemingly ‘left behind.’ The study of patients who are afflicted early in life with HD has become imperative, with this Special Issue representing just the beginning of the required effort to address this urgent need.
Huntington’s disease --- CAG repeat --- mutant huntingtin (mHTT) --- therapeutics --- neurodegeneration --- juvenile Huntington’s disease --- pediatric Huntington’s disease --- early-onset Huntington’s disease --- personal experiences --- caregivers --- case series --- juvenile-onset Huntington’s disease --- T1-Rho --- neuroimaging --- behavioral regulation --- executive function --- trinucleotide repeat disorder --- CAG --- motor onset --- juvenile-onset Huntington’s Disease --- autonomic --- n/a --- Huntington's disease --- juvenile Huntington's disease --- pediatric Huntington's disease --- early-onset Huntington's disease --- juvenile-onset Huntington's disease --- juvenile-onset Huntington's Disease
Choose an application
In 1993, the genetic mutation responsible for Huntington's disease (HD) was identified. Considered a milestone in human genomics, this discovery has led to nearly two decades of remarkable progress that has greatly increased our knowledge of HD, and documented an unexpectedly large and diverse range of biochemical and genetic perturbations that seem to result directly from the expression of the mutant huntingtin gene. Neurobiology of Huntington's Disease: Applications to Drug Discovery presents a thorough review of the issues surrounding drug discovery and development for the treatment of this
Huntington's disease --- Neuropharmacology. --- Pathophysiology. --- Molelcular aspects.
Listing 1 - 10 of 60 | << page >> |
Sort by
|